Nature Reviews Rheumatology - Table of Contents alert Volume 10 Issue 1

TABLE OF CONTENTS
January 2014 Volume 10 Number 1
Impact Factor 9.745 *	In this issue Research Highlights News and Views Reviews Perspectives Also this month  Featured article: Progress in intra-articular therapy Christopher H. Evans, Virginia B. Kraus & Lori A. Setton
Subscribe   Facebook   RSS   Recommend to library   Twitter
Advertisement
Nature Outlook The Spine   Combating paralysis with drugs, stem cells and robotics  Access the Outlook free online for six months.  Produced with support from: Mesoblast
RESEARCH HIGHLIGHTS Top Osteoarthritis: Targeting Rac1 via microparticle-based drug delivery system protects OA cartilage in vivo Published online: 10 December 2013 p1 | doi:10.1038/nrrheum.2013.192 PDF Rheumatoid arthritis: Prevotella copri associated with new-onset untreated RA Published online: 26 November 2013 p2 | doi:10.1038/nrrheum.2013.187 PDF Rheumatoid arthritis: Understanding hypercitrullination in rheumatoid arthritis Published online: 19 November 2013 p3 | doi:10.1038/nrrheum.2013.182 PDF Fracture repair: Could blockade of Notch signalling promote fracture repair? Published online: 26 November 2013 p3 | doi:10.1038/nrrheum.2013.186 PDF Bone diseases: Sclerostin neutralization—a viable pathway for OPPG? Published online: 03 December 2013 p4 | doi:10.1038/nrrheum.2013.189 PDF Osteoarthritis: Lack of Nfatc1 and Nfatc2: a new mouse model of OA Published online: 03 December 2013 p4 | doi:10.1038/nrrheum.2013.190 PDF IN BRIEF Rheumatoid arthritis: Viral immunity affects RA treatment | Therapy: Pre-natal glucocorticoids and childhood mental health | Rheumatoid arthritis: RA complications after arthroplasty | Osteoarthritis: Exercise reduces risk of total hip replacement PDF Rheumatology JOBS of the week 6 PhD and 2 MD Fellowships in Translational Rheumatology Deutsches Rheuma-Forschungszentrum Berlin (DRFZ) Postdoc in Autoimmunity and Tolerance University of Chicago More Science jobs from
NEWS AND VIEWS		Top
Spondyloarthritis: Gut inflammation in SpA: flagellin joins the dance? Peggy Jacques & Dirk Elewaut Published online: 10 December 2013 p5 | doi:10.1038/nrrheum.2013.191 New studies demonstrate the development of anti-flagellin antibodies in patients with ankylosing spondylitis. Does their presence point to mucosal dysregulation as a pathogenic mechanism of the disease? Full Text | PDF
Rheumatoid arthritis: New EULAR guidelines for RA: a job well done Joel M. Kremer Published online: 03 December 2013 p6 | doi:10.1038/nrrheum.2013.188 The 2013 update of the EULAR recommendations for the treatment of rheumatoid arthritis has evolved in several domains, and has, for the first time, elevated non-TNF-inhibitor biologic agents to the same status as TNF inhibitors. These transparently derived and scholarly recommendations will contribute to the evolving dialogue on the proper use of these agents. Full Text | PDF
Crystal arthritis: Environment and genetics in gout: a maze for clinicians? Fernando Perez-Ruiz & Ana María Herrero-Beites Published online: 12 November 2013 p8 | doi:10.1038/nrrheum.2013.173 The association of environmental dietary factors and polymorphisms of urate transporters with an increased risk of gout has been well established. Nevertheless, the influence of genetics and diet on serum urate concentrations, and the clinical relevance to individual patients, seems to be limited. Full Text | PDF
REVIEWS		Top
Progress in intra-articular therapy Christopher H. Evans, Virginia B. Kraus & Lori A. Setton Published online: 05 November 2013 p11 | doi:10.1038/nrrheum.2013.159 If a drug is intended to work in a joint, then direct injection seems likely to be an appropriate route of delivery, to minimize adverse events and limit the amount of therapeutic agent required. Ensuring such a drug remains in the joint long enough to produce an effect, however, is another matter. Successes seen, lessons learned, and developmental prospects in intra-articular therapy are explored in this Review. Abstract | Full Text | PDF
Treatment of systemic lupus erythematosus: new therapeutic avenues and blind alleys Aikaterini Thanou & Joan T. Merrill Published online: 08 October 2013 p23 | doi:10.1038/nrrheum.2013.145 Despite our increased knowledge of the complex pathways of immune dysregulation that occur in systemic lupus erythematosus, advanced-phase clinical trials of new biologic agents have repeatedly failed to achieve their clinical end points. In this Review, the authors discuss the progress and pitfalls that have been faced by some of the investigational treatments in this field. Abstract | Full Text | PDF
Standardization of autoantibody testing: a paradigm for serology in rheumatic diseases Pier Luigi Meroni, Martina Biggioggero, Silvia S. Pierangeli, Joanna Sheldon, Ingrid Zegers & Maria Orietta Borghi Published online: 26 November 2013 p35 | doi:10.1038/nrrheum.2013.180 Autoantibody testing is key for the diagnosis, classification and management of systemic autoimmune rheumatic diseases; however, issues regarding the reproducibility and reliability of these tests currently limit their usefulness. Approaches to harmonize autoantibody tests, including the development of technical guidelines and the availability of suitable reference materials for calibration and quality control, are discussed in this Review. Abstract | Full Text | PDF
Role of cytokines in intervertebral disc degeneration: pain and disc content Makarand V. Risbud & Irving M. Shapiro Published online: 29 October 2013 p44 | doi:10.1038/nrrheum.2013.160 Intervertebral disc (IVD) degeneration is a common cause of back, neck, and radicular pain. High levels of a number of inflammatory cytokines that are secreted by IVD cells characterize, and are involved in the pathogenesis of, IVD degeneration. In this comprehensive Review, the authors describe the key inflammatory cytokines that are involved in different phases of disc degeneration, and they describe the outcomes of the clinical studies that have investigated blocking cytokine function. Abstract | Full Text | PDF
PERSPECTIVES		Top
OPINION The landscape of comparative effectiveness research in rheumatology Esi Morgan DeWitt & Hermine I. Brunner Published online: 24 September 2013 p57 | doi:10.1038/nrrheum.2013.140 Comparative effectiveness research (CER) takes the clinical characteristics of patients into account to determine the most beneficial treatments. Here, the methodological approaches and the analytical challenges of CER are described, as well as the considerations needed to ensure high-standards of CER in rheumatology. Abstract | Full Text | PDF
Advertisement
NatureJournals app for iPad The NatureJournals app for iPad now boasts over 25 Nature-branded titles. Subscribe to any journal in the app for $35.99* and gain access to world class research on the move. www.nature.com/content/app/anytitleoffer *Apple exchange rates apply. Limited time offer available on all journals except Scientific Reports. iPad is a trademark of Apple Inc.
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events

*Journal Citation Reports, Thomson, 2012. Nature Reviews Rheumatology was previously published as Nature Clinical Practice Rheumatology.

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our feedback department Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2014 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.